Quizartinib 26.5 mg (Vanflyta) is a medication used to treat acute myeloid leukemia (AML), particularly in patients with FLT3-ITD mutations. It is marketed under the brand name Vanflyta and is a FLT3 inhibitor that works by blocking the activity of the FLT3 receptor. This receptor is involved in the growth and survival of AML cells, and inhibiting it can help slow or stop the growth of the cancer.

Quizartinib 26.5 mg (Vanflyta)

Product Overview: Quizartinib 26.5 mg (Vanflyta) is an oral FLT3 inhibitor used for the treatment of acute myeloid leukemia (AML) in patients with a FLT3-ITD mutation. By inhibiting the FLT3 receptor, Vanflyta helps slow or stop the growth of leukemia cells, improving outcomes for patients with this mutation. Quizartinib is indicated for use as part of a treatment regimen for newly diagnosed AML patients who are FLT3-ITD positive.

Key Benefits:

• Targeted therapy for patients with FLT3-ITD mutations in AML.
• Oral administration for convenient treatment at home.
• Inhibits the FLT3 receptor, which is involved in leukemia cell survival and proliferation.
• Shown to improve overall survival and reduce relapse rates in patients with FLT3 mutations.

Indications:

• Acute myeloid leukemia (AML) in FLT3-ITD positive patients.
• Used in patients who have not previously received treatment or in those who have relapsed or are refractory to other therapies.

Dosage:

• 26.5 mg taken orally once daily.
• The recommended dose may vary based on individual factors, and the healthcare provider will adjust the dosage accordingly. It is important to follow the prescribed dosing schedule for the best treatment results.

Precautions:

• QT prolongation: Quizartinib can cause QT interval prolongation, so ECG monitoring is essential during treatment.
• Infection risk: Quizartinib can lower white blood cell counts, increasing the risk of infections. Patients should be monitored for signs of infection.
• Liver function: Regular liver function tests should be done to monitor for potential liver-related side effects.
• It is not recommended during pregnancy or breastfeeding, and alternative therapies should be considered.

Common Side Effects:

• Nausea
• Fatigue
• Fever
• Diarrhea
• Decreased appetite
• Liver enzyme elevations
• Increased risk of infections

Packaging:

• Quizartinib 26.5 mg (Vanflyta) is provided in a [insert packaging type] for safe and convenient use. Ensure the tablets are taken as directed by a healthcare provider.

Important Notes:

• Quizartinib should be taken exactly as prescribed by a healthcare provider.
• Regular monitoring of blood counts, liver function, and electrocardiograms (ECGs) is necessary to ensure the safety and effectiveness of the treatment.
• Store in a cool, dry place, away from direct sunlight, and keep out of reach of children.